Puma Biotechnology Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
$0.55next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
NERLYNX Net Product Sales Quarterly42MTarget: 202000000 to 206000000
Total Revenue Quarterly44.8MTarget: 222000000 to 229000000
Research and Development (R&D) Expenses Quarterly19.8M
Watch Items
- ALISCA-Breast1 Phase II Trial Enrollment ExpansionTrigger: Expansion of enrollment in combination with endocrine treatment in chemotherapy-naïve HER2-negative, HR-positive metastatic breast cancerAction: Monitor clinical trial updates and biomarker-focused population data in H2 2026
- ALISCA-Lung1 Phase II Trial Enrollment ExpansionTrigger: Expansion of alisertib monotherapy trial for extensive-stage small cell lung cancerAction: Monitor clinical trial updates and patient enrollment progress in H2 2026
- ALISCA-Breast1 Phase II Trial Updated Data PresentationTrigger: Presentation of updated clinical dataAction: Review clinical efficacy and safety results in Q4 2026
Research as of 20 Jun 2026